Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.25 (-1.79%)
Spread: 0.50 (3.704%)
Open: 14.00
High: 14.00
Low: 13.75
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Company

29 Mar 2006 07:02

Angle PLC29 March 2006 For Immediate Release 29 March 2006 ANGLE plc ('ANGLE' or 'the Company') New Venture Company: InnoMatica Ltd ANGLE plc ('ANGLE'), the venture management and consulting company specialisingin the commercialisation of technology, is pleased to announce the launch of itslatest venture company, InnoMatica Ltd ('InnoMatica'). In accordance with ANGLE's Progeny(R) process for creating new ventures,InnoMatica has secured intellectual property that is set to revolutionise theUS$1.2bn per annum global market for percussive power tools by reducing operatorexposure to vibration, the principal cause of medical conditions such asVibration White Finger (VWF). The technology has been developed over ten yearsby a team of leading engineers, academics from the University of Cambridge andmembers of the power tools industry. The scale of the vibration problem is substantial. In 2001, over 35% ofemployer's liability insurance claims were for Hand Arm Vibration Syndrome(HAVS), a debilitating condition caused by exposure to hand transmittedvibration. The Health and Safety Executive (HSE) estimates that there are around300,000 sufferers of VWF, the most common form of HAVS, in the UK, with around 2million people regularly exposed to high levels of vibration. Costs of settlinga single VWF claim can exceed £200,000. Since the implementation throughout Europe of the Physical Agents (Vibration)Directive (approved by the UK Parliament as The Control of Vibration at WorkRegulations, July 2005), employers have been bound to adhere to specific limitson employee exposure to vibration in the workplace. The only method ofsignificantly reducing the vibrations generated by percussive power tools, suchas road breakers, is by increasing the mass of the tool; yet practical andregulatory issues prevent the movement of such heavy tools. As a result,employers have had to either limit the time a single employee may use a tool oruse deliberately underpowered tools in order to comply with the regulations. InnoMatica holds the solution to this problem in the form of its Variable MassTechnology (VMtechnologyTM). This technology reduces tool vibration to a levelthat allows a single operator to use a powerful percussive power tool for up tofour times longer than existing products. This not only removes the need fortime limits or power reduction, but also provides the operator with a much saferand easier to use tool. In accordance with ANGLE's Progeny(R) process for creating new ventures, ANGLE'splan is to build a strong commercial offering, seeking a return on itsinvestment in the medium term. ANGLE expects to invest up to £400,000 in theProgeny(R) venture, which is presently wholly owned by ANGLE. Once InnoMaticahas exercised its option to acquire the technology, ANGLE's equity stake in theCompany will be 61%. ANGLE's Chief Executive, Andrew Newland, said: "The power tools and construction industries are worth US$1.2bn per annum, andthey have long awaited a solution to the injuries caused from vibration powertools. We are delighted to be at the forefront of a technology that dramaticallyenhances productivity, not only solving the financial and legislative issues butalso addressing human safety." Chief Technology Officer of InnoMatica, Dott. Giovanni Bisutti, said: "InnoMatica's technology provides a genuine new standard for health, safety,productivity and operator comfort in percussive power tools. We intend toaddress the major legislative and productivity issues currently facing theindustry." For further information ANGLE plc +44 1483 295830Andrew Newland, Chief ExecutiveStephen Bence, Director of New Ventures Buchanan Communications +44 20 7466 5000Richard Darby, Suzanne Brocks, James Strong, Amy Rajendran Note to editors: About ANGLE Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE operates from officesin the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found atwww.angleplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Mar 20217:00 amRNSUpdate on submission for FDA clearance
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSResearch confirms high performance of Parsortix
12th Jan 20217:00 amRNSChange of Auditor
5th Jan 20217:00 amRNSIssue of Equity
9th Dec 20207:00 amRNSParsortix can capture single cancer cell in sample
20th Nov 20204:18 pmRNSHolding(s) in Company
18th Nov 20204:51 pmRNSHolding(s) in Company
13th Nov 202010:46 amRNSResult of General Meeting
3rd Nov 20202:54 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSInterim Results
27th Oct 20206:28 pmRNSResult of Placing & Notice of General Meeting
27th Oct 20207:00 amRNSAccelerated bookbuild to raise up to £20m
20th Oct 20207:00 amRNSSubmission accepted by FDA for substantive review
28th Sep 20207:00 amRNSIssue of LTIP Options and Share Options
28th Sep 20207:00 amRNSANGLE announces completion of FDA submission
23rd Sep 20207:00 amRNSPotential treatment strategy to limit metastasis
11th Sep 20203:35 pmRNSHolding(s) in Company
11th Sep 20203:30 pmRNSHolding(s) in Company
2nd Sep 20201:49 pmRNSNotification of Interim Results and Webcast
2nd Sep 202010:00 amRNSHolding(s) in Company
27th Aug 20203:13 pmRNSResult of 2020 Annual General Meeting
18th Aug 20209:30 amRNSHolding(s) in Company
14th Aug 20207:00 amRNSParsortix use to assess response to immunotherapy
6th Aug 202012:20 pmRNSHolding(s) in Company
5th Aug 20207:00 amRNSNotice of AGM and Posting of Annual Report
20th Jul 20207:00 amRNSStudy: Parsortix use in metastatic breast cancer
8th Jul 20205:35 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
25th Jun 20207:00 amRNSPreliminary Results
22nd Jun 20207:00 amRNSBlood donations recommenced for FDA studies
29th May 20207:00 amRNSNotice of Results
12th May 20207:00 amRNSCTC potential as biomarker in MET inhibitor trials
4th May 20207:00 amRNSLeading cancer centre publishes Parsortix workflow
28th Apr 20207:00 amRNSBusiness Update
17th Apr 20207:00 amRNSParsortix performance in head and neck cancer
3rd Mar 20207:00 amRNSAssessing risk of brain metastasis in lung cancer
27th Feb 20207:00 amRNSParsortix outperforms other CTC systems in RCC
25th Feb 20207:00 amRNSANGLE announce Tri-Con presentation with BioView
17th Feb 20207:00 amRNSData demonstrates key advantages of Parsortix
11th Feb 20207:00 amRNSStudy demonstrates Parsortix potential in melanoma
3rd Feb 20209:10 amRNSIssue of Equity
30th Jan 20207:00 amRNSInterim Results
30th Jan 20207:00 amRNSChange of accounting reference date
22nd Jan 20207:00 amRNSSuccessful face-to-face meeting with FDA
8th Jan 202012:33 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.